Emglev Therapeutics
Emglev is a biotechnology company established in 2023 as a spin-off of Institut Curie dedicated to the discovery and the development of transformative immunotherapies to address unmet medical needs in oncology. By leveraging its unique proprietary platform, expertise and innovative approach, Emglev unlocks the current barriers of conventional antibody discovery to provide unique targets and sdAbs selected fully in vitro and validated for therapeutic applications in any format against any target. At Emglev Therapeutics, we have assembled an experienced, interdisciplinary team with a unique vision : to unlock the next level of immunotherapies for the benefit of the patients with high unmet needs.
7-day free trial · no credit card
Verified contacts
1
available on Kipplo
LinkedIn employees
1 to 10
headcount range
Open roles
—
no listings
Distinct roles
0
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 1 verified contacts at Emglev Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
1 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Sign up to unlock all 1 contacts at Emglev Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 1 verified contacts at Emglev Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.